Decheng Capital LLC Q4 2024 Filing
Filed February 14, 2025
Portfolio Value
$466.2B
Holdings
28
Report Date
Q4 2024
Filing Type
13F-HR
All Holdings (28 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | CGONCG ONCOLOGY INC | 6,371,669 | $182.7B | 39.20% | |
| 2 | NUVBNuvation Bio Inc. | 25,954,439 | $69.0B | 14.81% | |
| 3 | UPBUpstream Bio Inc. | 3,285,293 | $54.0B | 11.58% | |
| 4 | NAMSNEWAMSTERDAM PHARMA CO NV | 770,000 | $19.8B | 4.24% | |
| 5 | ILMNIllumnia, Inc. | 94,767 | $12.7B | 2.72% | |
| 6 | RCUSArcus Biosciences, Inc | 808,789 | $12.0B | 2.58% | |
| 7 | KRYSKRYSTAL BIOTECH INC | 76,772 | $12.0B | 2.58% | |
| 8 | RVMDREVOLUTION MEDICINES INC(NSM) | 226,000 | $9.9B | 2.12% | |
| 9 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 171,600 | $9.3B | 1.99% | |
| 10 | CRNXCRINETICS PHARMACEUTICALS IN | 167,958 | $8.6B | 1.84% | |
| 11 | BYSIBeyondSpring Inc. | 4,882,651 | $8.0B | 1.71% | |
| 12 | MRUSMERUS NV | 189,098 | $8.0B | 1.71% | |
| 13 | LYELLyell Immunopharma, Inc. | 11,909,341 | $7.6B | 1.63% | |
| 14 | ZNTLZentalis Pharmaceuticals Inc. | 2,338,095 | $7.1B | 1.52% | |
| 15 | ACLXARCELLX INC | 84,377 | $6.5B | 1.39% | |
| 16 | PHATPHATHOM PHARMACEUTICALS INC | 694,254 | $5.6B | 1.21% | |
| 17 | ACRSAclaris Therapeutics, Inc. | 2,266,667 | $5.6B | 1.21% | |
| 18 | LEGNLEGEND BIOTECH CORP-ADR | 153,558 | $5.0B | 1.07% | |
| 19 | CYTKCYTOKINETICS INC | 100,000 | $4.7B | 1.01% | |
| 20 | BNTXBiontech SE-ADR | 40,000 | $4.6B | 0.98% | |
| 21 | AURAAura Biosciences, Inc. | 515,555 | $4.2B | 0.91% | |
| 22 | EQEquillium Inc. | 4,447,308 | $3.3B | 0.71% | |
| 23 | FDMT4D MOLECULAR THERAPEUTICS IN | 400,000 | $2.2B | 0.48% | |
| 24 | VERAVERA THERAPEUTICS INC | 49,767 | $2.1B | 0.45% | |
| 25 | ATRCAtriCure Inc. | 26,797 | $818.9M | 0.18% | |
| 26 | PYXSPyxis Oncology, Inc (formerly Apexigen) | 326,810 | $509.8M | 0.11% | |
| 27 | GRALGRAIL INC | 9,684 | $172.9M | 0.04% | |
| 28 | NUVB/WSNuvation Bio Inc. | 646,057 | $148.6M | 0.03% |